Cancer News: Overview of KEYNOTE-671 & NADIM II Trials by Dr. Lei Deng

Cancer News: Overview of KEYNOTE-671 & NADIM II Trials by Dr. Lei DengПодробнее

ESMO 2023 Lung Cancer Highlights – Keynote 671 | ALINA | TropionLung01 | Oncology BrothersПодробнее

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Mock interview of Lei DengПодробнее

For NSCLC Neoadjuvant Adjuvant or BothПодробнее

Pembro plus chemo followed by resection and adjuvant pembro improves on SOC for early NSCLCПодробнее

The rationale and trial design of the NADIM II trialПодробнее

Pre-treatment ctDNA levels significantly predicts OS and PFS in NADIM IIПодробнее

Why do kidney cancer clinical trials matter? | National Kidney FoundationПодробнее

Checkmate 816: Combining Chemo and Opdivo - ASCO Lung Review 2022Подробнее

Key themes in lung cancer at NACLC 2022Подробнее

Perioperative Chemoimmunotherapy in Lung Cancer | NEJMПодробнее

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanomaПодробнее

Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLCПодробнее

Cancer Research and Treatment Initiatives—Nuclear MedicineПодробнее

PD-L1 expression in early NSCLC: Interpreting the data so far | Heather Wakelee & Nasser AltorkiПодробнее